Clovis Oncology, Inc. (NASDAQ:CLVS) surged +5.94% and closed the trade at $ 32.45. The company recorded a trading capacity of 4.65 million shares above its three months average daily volume of 1.96 million shares. During the last trade, shares reached to high price of $32.63 and touched the low price of $30.14. The stock’s 50-day moving average is noted at $19.77 and its 200-day moving average is stands at $16.76.
Additionally, the company has EPS of -11.28. The company has market capitalization of $1.25B.
Currently Clovis Oncology, Inc. (CLVS) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “3″ Analysts”. “0” rated “Sell” for the company. “5” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $22.50 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $30.00 however minimum price target advised by analysts is $12.00. The Median price target for the stock is measured at $22.50.
Presently, Analysts decided consensus EPS estimate of $-2.01 for present quarter and one month ago projected EPS estimate was at $-2.01. If we take a look at back 3 month ago, consensus EPS estimate was $-2.00.
A current consensus EPS estimate for next quarter is at $-1.72 and 3 month ago EPS forecast was $-1.80. Have a look at back 1 month ago, consensus EPS forecast was seen at $-1.74.
For current fiscal year, most recent EPS estimate is set at $-9.32 based on Analyst consensus and three month ago consensus EPS opinions was at $-8.06. During period one month ago, consensus EPS forecast was decided at $-9.20.
A current consensus EPS projection for next fiscal year is observed at $-4.86 and one month ago consensus EPS forecast was at $-4.85. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-5.09 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 3 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 6 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Hold derived from brokerage firms, according to FactSet. 2 said a “Buy Rating” and 0 announced “Overweight Rating”. 6 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.